If approved, patisiran will be the first RNAi therapeutic on the market. 

Researchers engineer bacterial CRISPR-Cas13 to knock down RNA in mammalian cells.

Two freely available databases include data on hundreds of human cancer cell lines. 

A new study adds to the evidence that mammalian cells can use small interfering RNAs to defend against viruses, but questions remain about physiological importance.

This month, the EPA registered four products that include RNA interference technology intended to control corn rootworms. 

Our guide to all known forms of RNA, from cis-NAT to vault RNA and everything in between.

A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

Plants and fungi can use conserved RNA interference machinery to regulate each other’s gene expression—and scientists think they can make use of this phenomenon to create a new generation of pesticides.

Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.